KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Moderna (MRNA) EPS (Weighted Average and Diluted) (2019 - 2026)

Moderna (MRNA) has disclosed EPS (Weighted Average and Diluted) for 8 consecutive years, with -$3.4 as the latest value for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) fell 34.92% year-over-year to -$3.4; the TTM value through Mar 2026 reached -$8.15, up 6.64%, while the annual FY2025 figure was -$7.26, 21.77% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$3.4 in Q1 2026 for Moderna, down from -$2.11 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $8.58 in Q1 2022 and bottomed at -$9.53 in Q3 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.73, with a median of -$2.11 recorded in 2025.
  • Year-over-year, EPS (Weighted Average and Diluted) soared 202.11% in 2022 and then crashed 1800.0% in 2025.
  • Moderna's EPS (Weighted Average and Diluted) stood at $3.66 in 2022, then crashed by 84.7% to $0.56 in 2023, then plummeted by 619.64% to -$2.91 in 2024, then rose by 27.49% to -$2.11 in 2025, then plummeted by 61.14% to -$3.4 in 2026.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$3.4, -$2.11, and -$0.51 for Q1 2026, Q4 2025, and Q3 2025 respectively.